Page 156 - 南京医科大学自然版

第45卷第5期
·742 · 南 京 医 科 大 学 学 报 2025年5月

［参考文献］ tive study［J］. Cancer Med，2021，10（1）：188-198
［12］SOCIETY A T，SOCIETY E R. American Thoracic Society/
［1］ NAIDOO J，PAGE D B，LI B T，et al. Toxicities of the anti⁃
European Respiratory Society International Multidisci⁃
PD⁃1 and anti⁃PD⁃L1 immune checkpoint antibodies［J］.
plinaryConsensusClassificationoftheIdiopathicInterstitial
Ann Oncol，2015，26（12）：2375-2391
Pneumonias. This joint statement of the American Thoracic
［2］ KHUNGER M，RAKSHIT S，PASUPULETI V，et al. Inci⁃
Society（ATS），and the European Respiratory Society
dence of pneumonitis with use of programmed death 1
（ERS）was adopted by the ATS board of directors，June
and programmed death⁃ligand 1 inhibitors in non⁃small
2001 and by the ERS Executive Committee，June 2001［J］.
cell lung cancer：a systematic review and meta⁃analysis of
Am J Respir Crit Care Med，2002，165（2）：277-304
trials［J］. Chest，2017，152（2）：271-281
［13］NISHINO M，RAMAIYA N H，AWAD M M，et al. PD⁃1
［3］ NISHINO M，GIOBBIE⁃HURDER A，HATABU H，et al.
inhibitor ⁃ related pneumonitis in advanced cancer pa⁃
Incidence of programmed cell death 1 inhibitor ⁃ related
tients：radiographic patterns and clinical course［J］. Clin
pneumonitis in patients with advanced cancer：a systematic
Cancer Res，2016，22（24）：6051-6060
review and meta⁃analysis［J］. JAMA Oncol，2016，2（12）：
［14］KALISZ K R，RAMAIYA N H，LAUKAMP K R，et al. Im⁃
1607-1616 mune checkpoint inhibitor therapy⁃related pneumonitis：
［4］ TONG Z Q，WU D Y，LIU D，et al. Incidence risk of PD⁃1/
patterns and management［J］. Radiographics，2019，39
PD⁃L1⁃related pneumonia and diarrhea in non⁃small cell
（7）：1923-1937
lung cancer（NSCLC）patients：a systematic review and
［15］LARSEN B T，CHAE J M，DIXIT A S，et al. Clinical and
meta ⁃ analysis of randomized controlled trials［J］. Eur J
histopathologic features of immune checkpoint inhibitor⁃
Clin Pharmacol，2021，77（8）：1079-1088 related pneumonitis［J］. Am J Surg Pathol，2019，43（10）：
［5］ ATCHLEY W T，ALVAREZ C，SAXENA⁃BEEM S，et al.
1331-1340
Immune checkpoint inhibitor⁃related pneumonitis in lung ［16］SURESH K，NAIDOO J，LIN C T，et al. Immune check⁃
cancer：real ⁃ world incidence，risk factors，and manage⁃
point immunotherapy for non⁃small cell lung cancer：ben⁃
ment practices across six health care centers in north Car⁃ efits and pulmonary toxicities［J］. Chest，2018，154（6）：
olina［J］. Chest，2021，160（2）：731-742 1416-1423
［6］ NAIDOO J，WANG X，WOO K M，et al. Pneumonitis in ［17］中华医学会呼吸病学分会肺癌学组. 免疫检查点抑制
patients treated with anti ⁃ programmed death ⁃ 1/pro⁃ 剂相关肺炎诊治专家共识［J］. 中华结核和呼吸杂志，
grammed death ligand 1 therapy［J］. J Clin Oncol，2017， 2019，42（11）：820-825
35（7）：709-717 Lung Cancer Group，Chinese Thoracic Society. Expert
［7］ PANG L，XIE M，MA X D，et al. Clinical characteristics consensus on prevention and treatment of checkpoint in⁃
and therapeutic effects of checkpoint inhibitor ⁃ related hibitor pneumonitis［J］. Chinese Journal of Tuberculosis
pneumonitis in patients with non⁃small cell lung cancer［J］. and Respiratory Diseases，2019，42（11）：820-825
BMC Cancer，2023，23（1）：203 ［18］National Comprehensive Cancer Network. Management of
［8］ CHO J Y，KIM J，LEE J S，et al. Characteristics，inci⁃ immunotherapy⁃related toxicities，version 1.2024［EB/OL］.
dence，and risk factors of immune checkpoint inhibitor⁃ （2023-12-07）［2024-12-15］. https：//www.nccn.org
related pneumonitis in patients with non⁃small cell lung ［19］BRAHMER J R，LACCHETTI C，SCHNEIDER B J，et al.
cancer［J］. Lung Cancer，2018，125：150-156 Management of immune ⁃ related adverse events in pa⁃
［9］ SURESH K，VOONG K R，SHANKAR B，et al. Pneumo⁃ tients treated with immune checkpoint inhibitor therapy：
nitis in non ⁃ small cell lung cancer patients receiving American society of clinical oncology clinical practice
immune checkpoint immunotherapy：incidence and risk guideline［J］. J Clin Oncol，2018，36（17）：1714-1768
factors［J］. J Thorac Oncol，2018，13（12）：1930-1939 ［20］SCHNEIDER B J，NAIDOO J，SANTOMASSO B D，et al.
［10］ YIN J Q，WU Y J，YANG X，et al. Checkpoint inhibitor Management of immune ⁃ related adverse events in pa⁃
pneumonitis induced by anti⁃PD⁃1/PD⁃L1 therapy in non⁃ tients treated with immune checkpoint inhibitor therapy：
small ⁃ cell lung cancer：occurrence and mechanism［J］. ASCO guideline update［J］. J Clin Oncol，2021，39（36）：
Front Immunol，2022，13：830631 4073-4126
［11］ WANG H P，ZHAO Y W，ZHANG X T，et al. Clinical ［21］ PUZANOV I，DIAB A，ABDALLAH K，et al. Managing
characteristics and management of immune checkpoint in⁃ toxicities associated with immune checkpoint inhibitors：
hibitor⁃related pneumonitis：a single⁃institution retrospec⁃ consensus recommendations from the Society for Immuno⁃